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Key Points
• Loss of ATR signaling is
cytotoxic to AML cells
in combination with
gemcitabine and
hydroxyurea via the
induction of replication
stress.
• A small molecule
inhibitor of ATR in
combination with
gemcitabine completely
eradicates AML in an
orthotopic xenograft
mouse model.
Theataxia telangiectasia andRad3-related (ATR)proteinkinasepromotes cancer cell survival
by signaling stalled replication forks generated by replication stress, a common feature of
many cancers including acutemyeloid leukemia (AML). Here we show that the antileukemic
activity of the chemotherapeutic nucleoside analogs hydroxyurea and gemcitabine was
signiﬁcantly potentiated by ATR inhibition via a mechanism involving ribonucleotide
reductase (RNR) abrogation and inhibition of replication fork progression. When adminis-
tered in combinationwith gemcitabine, an inhibitor of theM1RNR subunit, the ATR inhibitor
VX-970, eradicated disseminated leukemia in an orthotopicmousemodel, eliciting long-term
survival and effective cure. These data identify a synergistic interaction between ATR
inhibition and RNR loss that will inform the deployment of small molecule inhibitors for the
treatment of AML and other hematologic malignancies.
Introduction
Oncogene expression drives cell proliferation and induces DNA replication stress via the dysregulation
of pathways essential for replication origin firing and fork progression.1 Replication stress promotes
genomic instability and renders cancer cells overly reliant on DNA damage response (DDR) pathways to
maintain proliferation and survival. Ataxia telangiectasia and Rad3-related (ATR) serine/threonine protein
kinase phosphorylates CHK1 in response to stalled replication forks.2-6 Activation of the ATR-CHK1
DDR pathway leads to cell cycle arrest and invokes mechanisms that prevent replication fork breakage
and premature mitotic entry before replication is completed.1
Acute myeloid leukemia (AML) is a genetically heterogenous malignancy characterized by recurrent
acquired somatic alterations that alter cell proliferation and differentiation leading to an accumulation of
immature blast cells in the bone marrow. Although many AML patients achieve complete morphologic
remission with nucleoside analog and anthracycline-based therapies, the 3-year survival is less than
30%.7 Many of the somatic driver mutations in AML are associated with the induction of replication
stress, includingMLL (KMT2A) gene fusions and mutations in TP53, RAS, and c-MYC.8,9 Efficient DDR
signaling, mediated via ATR-CHK1 signaling, is implicated in maintaining leukemia cell survival.
The induction of replication stress is also a key feature of chemotherapy agents used to treat AML, including
nucleoside analogs such as cytarabine, clofarabine, gemcitabine, and hydroxyurea,10 which are efficacious
via a mechanism in which DDR pathways become overwhelmed by high levels of DNA damage-induced
replication stress. We hypothesized that targeted inhibition of ATR-CHK1 signaling combined with
replication-stalling chemotherapy agents would generate a therapeutic window for treating AML with high
levels of endogenous replication stress. Here, we show that co-treatment with an ATR inhibitor significantly
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potentiates the antileukemic effects of hydroxyurea and gemcitabine in
AML cell lines and primary AML samples and completely eradicates
disseminated leukemia in an orthotopic mouse model of AML.We also
show that ATR inhibition is particularly efficacious in combination with
those chemotherapy agents that inhibit ribonucleotide reductase
(RNR), including hydroxyurea and particularly gemcitabine.
Materials and methods
Cell lines
HL-60, AML-2, AML-3, U937, THP-1, NB4, and MV4-11 cell lines were
from DSMZ (Braunschweig, Germany). MV4-11 pSLIEW cells are a
subclone ofMV4-11 engineered to express firefly luciferase. HL-60 ATRi
(con) and HL-60 ATRi (ind) are subclones of HL-60 with knockdown
of ATR. Cells were maintained in culture medium (CM) (RPMI 1640
medium supplementedwith 10% fetal bovine serum [FBS] and50mg/mL
penicillin/streptomycin) at 37°C in a humidified 5% CO2 incubator.
HEK293T cells were maintained in N-2-hydroxyethylpiperazine-N9-
2-ethanesulfonic acid–modified Dulbecco’s modified Eagle medium
6171 supplemented with 10% FBS, 50 mg/mL penicillin/streptomycin,
4 mM L-glutamine, 1 mM sodium pyruvate, and 500 mg/mL G418. The
identity of cell lines was confirmed by short tandem repeat profiling
(NewGene, Newcastle upon Tyne, United Kingdom) and tested for
mycoplasma using a MycoAlert kit (Lonza, Slough, United Kingdom).
Primary cultures
Diagnostic bone marrow aspirates were separated using Lymphoprep
(Stemcell Technologies, Cambridge, United Kingdom). Patients included
de novo AML1 (male, age 76 years), de novo AML2 (male, age 72 years),
de novo AML3 (female, age 66 years), de novo AML 4 (female, age
52 years), relapsed AML (female, age 56 years), therapy-related AML1
(t-AML) (pediatric male, previous chemotherapy for acute lymphoblastic
leukemia), and t-AML2 (male, previous chemotherapy for bowel cancer
and chronic myeloid leukemia). Mononuclear cells were washed in
phosphate-buffered saline and resuspended in enhanced CM (Iscove’s
modified Dulbecco’s medium supplemented with 20% FBS, 4 mM
L-glutamine, 50 mg/mL penicillin/streptomycin, 10 ng/mL interleukin-3,
and 20 ng/mL stem cell factor) for use in cytotoxicity assays. Samples
were collected after informed consent was provided via the Newcastle
Haematology Biobank (Ref: 12/NE/0395).
Normal bone marrow cells were obtained from 2 females (age 50 and
57 years) undergoing surgery for osteoarthritis. Samples were collected
after informed consent was provided and after approval by the Newcastle
and North Tyneside 1 Research Ethics Committee (Ref: 09/H0906/72).
In vivo mouse studies
Female 8-week old Rag22/2gc2/2.mice (Rag22/2Il2rg2/21293Balb/c)
were used for in vivo investigations11 in accordance with United
Kingdom Home Office Project License PPL60/4552. For intra-
femoral injection, 5 3 105 MV4-11 Luc1GFP1 cells in 20 mL CM
were injected through the knee into the femur marrow cavity. Mice
underwent regular noninvasive whole body imaging starting 7 days
postinjection. Anesthetized mice were injected intraperitoneally with
150mg/kg luciferin and imaged using an IVIS Spectrum in vivo imaging
system (Caliper Life Sciences, Waltham, MA). Total flux biolumines-
cence was quantitated in photons/second (p/s). Mice received
either 100 mg/kg gemcitabine (days 1, 4, 8, and 12), 60 mg/kg
VX-970 (days 1-5 and 8-12), both 100mg/kg gemcitabine (days 1, 4, 8,
and 12) and 60 mg/kg VX-970 (days 1-5 and 8-12), or vehicle only.
Gemcitabine (20 mg/mL in saline) was administered intraperitoneally,
and VX-970 (12 mg/mL in D-a-tocopherol polyethylene glycol 1000
succinate) was administered by oral gavage.
Mice were monitored for signs of disease progression and were
humanely euthanized if tumor diameter reached 15 mm or before
this point if there were any signs of animal suffering. Tissues
harvested during postmortem analysis were fixed in 10% neutral
buffered formalin, decalcified in 10% formic acid, and paraffin
embedded and sectioned at 4 mm. Serial sections were stained for
the human markers CD33, CD45, and Ki67 or with hematoxylin and
eosin for morphologic assessment by the Department of Pathology,
Royal Victoria Infirmary (Newcastle upon Tyne, United Kingdom).
Generation of cells with ATR knockdown
HL-60 ATRi (con) cells with constitutive ATR knockdown were
generated with verified ATR MISSION short hairpin RNA (shRNA)
lentiviral transduction particles (Sigma-Aldrich, Dorset, United Kingdom).
Briefly, lentiviral particles were incubated with cells in CM supplemented
with 8 mg/mL hexadimethrine bromide and centrifuged at 800g for
30 minutes at 32°C. HL-60 non-target control cells were generated
using MISSION non-target shRNA control transduction particles.
Transduced cells were selected for with 2 mg/mL puromycin.
For generation of HL-60 ATRi (ind) cells with inducible ATR knockdown,
shRNA lentivirus was produced by transfection of HEK293T cells
with the packaging vector pCMVD8.91, the envelope vector pMD2.G,
and a TRIPZ inducible lentiviral human ATR shRNA (GE Healthcare,
Buckinghamshire, United Kingdom). The expression of ATR shRNA
was induced by supplementing CM with 500 ng/mL doxycycline
48 hours before setting up cytotoxicity assays.
Transient RRM1 knockdown using siRNA
Exponentially growing cells were mixed with 1 mM Dharmacon
siGENOME Human RRM1 (6240) small interfering RNA (siRNA)
SMARTpool (GE Healthcare) or MISSION siRNA Universal Negative
Control #1 (Sigma-Aldrich) and electroporated at 260 V for 10 ms.
Potentiation assays
Reagents used in potentiation assays were from Sigma-Aldrich
unless otherwise stated. Gemcitabine, hydroxyurea, and clofarabine
were reconstituted in sterile dH2O. Cytarabine, fludarabine,
3-aminopyridine-2-carboxyaldehyde-thiosemicarbazone (3-AP), and
the ATR inhibitors VE-821 (Axon Medchem, Groningen, The Nether-
lands) and VX-970 (Selleck Chemicals, Munich, Germany) were
reconstituted in dimethyl sulfoxide (DMSO).
AML cell lines or primary mononuclear cells were seeded in CM or
enhanced CM, respectively, supplemented with either ATR inhibitor
or vehicle control. Cells were treated with increasing doses of
cytotoxic agent (or control) and incubated for 96 hours. For AML
cell lines, viable cells were identified by trypan blue dye exclusion
and were counted using a hemocytometer. Then, 10 mg/mL
resazurin sodium salt was added, plates were incubated for an
additional 6 hours, and fluorescence was determined using a plate
reader with excitation at 535 nm and emission at 590 nm. Survival
fractions were determined at each drug concentration relative
to vehicle controls. All assays were performed in triplicate and
means 6 standard deviation were calculated. Potentiation factors
(PFs) were calculated as the fold difference in mean survival fraction
between cells in the presence or absence of ATR inhibitor.
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Combination index (CI) was calculated using Compusyn and the
Chou-Talalay method12 with quantitative definitions for additive
effect (CI 5 1), synergism (CI ,1), and antagonism (CI .1) for
VE-821 in combination with hydroxyurea or gemcitabine.
Patient-derived cells were cultured in cytokine-supplemented media,
and proliferation was confirmed between 6 and 24 hours using the
RealTime-Glo MT assay (Promega, Madison, WI) (supplemental
Figure 1).
Cell cycle analysis
Exponentially growing cells were treated with 1 mM VE-821 (or
DMSO control) and 10 nM gemcitabine, 100 mM hydroxyurea, or
100 nM cytarabine (or vehicle control). Aliquots were removed,
and cells were fixed with ice-cold 70% (v/v) ethanol. Cells were
resuspended in phosphate-buffered saline supplemented with
20 mg/mL RNase A and 40 mg/mL propidium iodide, incubated at
room temperature in the dark for 10 minutes, and then analyzed using
a BD FACSCalibur flow cytometer (BD Biosciences, San Jose, CA).
DNA fiber assay
MV4-11 cells were seeded in CM with 5 nM gemcitabine, 15 mM
hydroxyurea, or 50 nM cytarabine for 1 hour and incubated with 25mM
5-iodo-29-deoxyuridine (IdU) for 40 minutes. Cells were resuspended
in CM supplemented with drug as above, 250 mM 5-chloro-29-
deoxyuridine (CldU), and 1 mM VE-821 (or DMSO control) for an
additional 40 minutes. Microscope slides were prepared as previously
described,13 and DNA fibers were studied by using a Leica DMR light
microscope. IdU and CldU tract lengths were measured using ImageJ
(Version 1.41o; National Institutes of Health) (conversion factor:
1 mm5 2.59 kb). A minimum of 100 forks were analyzed per treatment.
Western blotting
Cellular proteins were extracted using Phosphosafe (Millipore Ltd,
Watford, United Kingdom) and quantified by using a Pierce bicinchoninic
acid assay (Thermo Fisher Scientific, Cramlington, United Kingdom).
Proteins were separated using Novex NUPAGE 3% to 8% tris-acetate
gels (Invitrogen Life Technologies, Paisley, United Kingdom), transferred
to nitrocellulose membranes, and immunoblotted. Antibodies were
ATR (N-19; Santa Cruz Biotechnology, Heidelberg, Germany), pCHK1
(Ser345) (133D3; Cell Signaling Technology, Leiden, The Netherlands),
RRM1 (A-10; Santa Cruz Biotechnology), glyceraldehyde-3-phosphate
dehydrogenase (0411; Santa Cruz Biotechnology), and horseradish
peroxidase–conjugated secondary antibodies (Agilent Technologies,
Santa Clara, CA).
Statistical analysis
The Student t test (2-tailed), 2-way analysis of variance, or Mann-
Whitney U test was used to compare responses in the presence
and absence of ATRi. Overall survival data from mice were compared
by Kaplan-Meier survival analysis using a Mantel-Cox log-rank test. All
statistical tests were performed usingGraphPad Prism 6 or IBMSPSS
Statistics 22 software.
Results
Inhibition or RNA silencing of ATR potentiates
hydroxyurea and gemcitabine in AML cell lines
Phosphorylation of checkpoint kinase CHK1 was used as a marker
for ATR pathway activation. Treatment with 100 mM hydroxyurea
resulted in phosphorylation of CHK1 in AML cell lines AML-2,
AML-3, HL-60, MV4-11, NB4, THP-1, and U937 (Figure 1A). CHK1
phosphorylation was attenuated in all 7 AML cell lines when
hydroxyurea was coadministered with the ATR inhibitor VE-821
(Figure 1A), demonstrating that the ATR signaling pathway is active
in AML cells and that it can be inhibited by VE-821.
Treatment with VE-821 at a concentration (1 mM) that has no
single-agent activity did not consistently potentiate the antiprolifer-
ative effects of cytarabine, clofarabine, or fludarabine (supplemental
Figure 2), although there was some potentiation of clofarabine in
MV4-11 and of fludarabine and cytarabine in THP-1 (supplemental
Figure 2). However, there was consistent potentiation of hydroxy-
urea and particularly gemcitabine by VE-821 in all 7 AML cell lines
tested (Figure 1B-C), and CI analysis confirmed that VE-821 is
synergistic (CI ,1) with hydroxyurea and gemcitabine (Figure 1D).
AML cells were also treated with a second structurally unrelated
ATR inhibitor (NU6027),14 which also consistently potentiated the
antiproliferative effects of hydroxyurea and gemcitabine (Figure 1B-C;
supplemental Figure 2).
HL-60 cell clones expressing a constitutively active shRNA
construct (HL-60 ATR [con]) or a doxycycline-inducible shRNA
construct targeting ATR (HL-60 ATR [ind]) had reduced ATR
protein expression compared with control-transduced cells
(Figure 1E) and were sensitized to the antiproliferative effects
of hydroxyurea and particularly gemcitabine (Figure 1F-G). In contrast,
loss of ATR expression had weak or no effect on sensitivity to the
antiproliferative effects of cytarabine, clofarabine, or fludarabine
(supplemental Figure 3). These data demonstrate that loss of ATR
function mediated by small molecule inhibition or RNA silencing
sensitizes AML cells to the inhibitory effects of hydroxyurea and
gemcitabine.
ATRi attenuates replication fork progression and
induces S-phase arrest in combination with
gemcitabine and hydroxyurea
ATR protects cells against collapsed replication forks under conditions
of replicative stress.4,5,15 We hypothesized that ATRi in combination
with hydroxyurea or gemcitabine would lead to reduced replication fork
progression and S-phase arrest. Treatment with ATR inhibitor alone
did not affect the U937 cell cycle profile (Figure 2A), but single-agent
gemcitabine induced S-phase arrest discernible between 8 and
16 hours that was resolved by 24 hours (Figure 2A). VE-821 potentiated
gemcitabine-induced S-phase arrest (Figure 2A). This effect was also
seen in cells after treatment with an approximate equitoxic concentration
of hydroxyurea but was less pronounced (Figure 2A). Further-
more, treatment with 1 mM VE-821 significantly slowed replication fork
progression in combination with hydroxyurea (PF, 1.37; P , .001)
and particularly with gemcitabine (PF, 1.57; P , .001) (Figure 2B;
supplemental Figure 4), consistent with the cell cycle results. Treatment
of U937 cells with cytarabine also induced a pronouncedS-phase arrest
(Figure 2A) and replication fork arrest (supplemental Figure 4). However,
co-treatment with 1 mMVE-821 did not potentiate either S-phase arrest
or replication fork arrest (PF, 1.04; P 5 .222) (Figure 2A-B).
ATRi potentiates growth inhibition resulting from
ribonucleotide reductase (RNR) knockdown
The anticancer activities of gemcitabine and hydroxyurea are partly
mediated via inhibition of RNR, a protein involved in the de novo
22 MAY 2018 x VOLUME 2, NUMBER 10 DEPLOYMENT OF ATR INHIBITORS TO TREAT AML 1159
.For personal use onlyon June 11, 2019. by guest  www.bloodadvances.orgFrom 
030%
-
-
+
-
AML-2 AML-3 HL-60 MV4-11 NB4 THP-1 U937
-
+
+
+
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
-
-
+
-
-
+
+
+
17% 12% 41% 19% 44% 52% pChk1 inhibition
by VE-821 (%)
VE-821 (1 µM)
HU (100 µM)
pC
HK
1
(%
 re
lat
ive
ex
pr
es
sio
n)
ATR
pChk1
(S345)
GAPDH
50
100
A
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 25
HU (µM)
50
THP-1
PF 5.4
PF 23.6
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 25
HU (µM)
50
AML-2
PF 4.2
PF 17.4
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 25
HU (µM)
50
AML-3
PF 4.1
PF 40.0
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 50
HU (µM)
100
NB4
PF 3.8
PF 5.4
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 50
HU (µM)
100
MV4-11
PF 1.4
PF 9.6
0 100
HU (µM)
200
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
U937
PF 3.3
PF 8.4
Control
+ 10 µM NU6027
+ 1 µM VE-821
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 50
HU (µM)
100
HL-60
PF 3.3
PF 18.2
B
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 2.5
Gem (nM)
5
THP-1
PF 6.8
PF 33.3
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 0.5
Gem (nM)
1
AML-2
PF 4.7
PF 7.4
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 5
Gem (nM)
10
AML-3
PF 32.1
PF 14.0
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 5
Gem (nM)
10
HL-60
PF 22.8
PF 22.3
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 5
Gem (nM)
10
NB4
PF 9.4
PF 37.2
Ce
ll g
ro
wt
h 
(%
)
0.1
1
10
100
0 5
Gem (nM)
10
MV4-11
PF 5.6
PF 81.7
0.1
1
10
100
Ce
ll g
ro
wt
h 
(%
)
0 5
Gem (nM)
10
U937
PF 2.8
PF 51.8
Control
+ 10 µM NU6027
+ 1 µM VE-821
C
2
1.5
1
0.5
Co
m
bin
at
ion
 in
de
x
Fraction of cells affected
0
0 0.5 1
U937 (HU + VE-821)
MV4-11 (HU + VE-821)
U937 (GEM + VE-821)
MV4-11 (GEM + VE-821)
D
HL-60 NTC
Time (hr)
ATR
GAPDH
Doxycycline
(500 ng/ml)
0
-
24
-
48
-
72
-
96
-
HL-60 ATR (con)
0
-
24
-
48
-
72
-
96
-
HL-60 ATR (ind)
0
+
24
+
48
+
72
+
96
+
0
-
24
-
48
-
72
-
96
-
E
100
10
1
0.1
0
PF 4.6
100
HU (µM)
Ce
ll g
ro
wt
h 
(%
)
200
PF 3.4
100
10
1
0.1
Ce
ll g
ro
wt
h 
(%
)
0 100
HU (µM)
200
HL-60 NTC
HL-60 ATR (con)
HL-60 ATR (ind)
HL-60 ATR (ind)
+ 500 ng/ml dox
F
HL-60 NTC
HL-60 ATR (con)
HL-60 ATR (ind)
HL-60 ATR (ind)
+ 500 ng/ml doxPF 169.9
100
10
1
0.1Ce
ll g
ro
wt
h 
(%
)
Gem (nM)
0.01
0 1 2
PF 19.1
100
10
1
0.1Ce
ll g
ro
wt
h 
(%
)
0.01
Gem (nM)
0 1 2
G
Figure 1.
1160 FORDHAM et al 22 MAY 2018 x VOLUME 2, NUMBER 10
.For personal use onlyon June 11, 2019. by guest  www.bloodadvances.orgFrom 
biosynthesis of nucleotide precursors for DNA replication.16
Reduced deoxyribonucleotide triphosphate (dNTP) levels after
exposure to gemcitabine or hydroxyurea slows DNA replication
fork progression and induces S-phase arrest.17,18 Cellular response
to the resulting stalled replication forks is mediated by ATR
signaling.19 Given this shared mechanism of action, we hypothe-
sized that replication stalling as a result of loss of RNR expression is
potentiated by ATRi.
Mammalian RNRs consist of 2 homodimeric subunits that
associate to form a heterodimeric tetramer, with the larger
RRM1 dimer containing the catalytic site and the smaller dimer
consisting of 1 of 2 possible isoforms (RRM2 or RRM2B).20
Treatment with gemcitabine induces cellular expression of RNR in
pancreatic cancer cells,21 possibly as a mechanism to compen-
sate for inhibition of activity. Consistent with this model, we
observed increased expression of RRM1 in AML-3 cells treated
with gemcitabine and hydroxyurea but not with cytarabine
(Figure 3A). Cotreatment with VE-821 inhibited drug-induced
RRM1 upregulation, which was particularly apparent in
gemcitabine-treated cells (Figure 3A), providing further evidence
that the efficacy of this particular combination is mediated
via abrogation of RNR. Consistent with this hypothesis, siRNA-
mediated knockdown of RRM1 in AML-3 and U937 cells resulted in
a robust pCHK1 response, which was attenuated by VE-821
(Figure 3B). Furthermore, growth inhibition mediated via RRM1
knockdown was also potentiated by VE-821 (Figure 3A). Treatment
of cells with 3-AP, a non-nucleoside RNR inhibitor, induced a
pCHK1 response in AML-2, AML-3, and U937 that was attenuated
by VE-821 (Figure 3C). 3-AP exposure also reduced proliferation
that was potentiated by ATRi in all 3 cell lines (Figure 3D). These
data demonstrate that loss of RNR induces a pCHK1 response
that is signaled via ATR and that attenuation of this pathway by
VE-821 significantly potentiates the growth-inhibitory effects of
RNR inhibition in AML cells.
ATRi potentiates the cytotoxicity of hydroxyurea and
gemcitabine in primary AML samples ex vivo
The growth inhibitory effects of hydroxyurea and gemcitabine
were potentiated by VE-821 in the majority of AML patient
samples tested (Figure 4A-B), which included 3 adult patients
with de novo AML, a relapsed AML, a pediatric t-AML patient
(t-AML1), and an adult t-AML patient (t-AML2). Those samples in
which potentiation was not observed seemed to be intrinsically
chemotherapy resistant to either hydroxyurea (de novo AML3) or
gemcitabine (t-AML2). In contrast to primary AML samples, ATRi
did not potentiate the growth-inhibitory effects of hydroxyurea or
gemcitabine in primary bone marrow cells from healthy donors
(Figure 4C-D).
ATRi potentiates the cytotoxicity of gemcitabine in an
orthotopic mouse model of AML
We next determined whether ATRi could potentiate the activity of
gemcitabine in an orthotopic mouse model of AML treated with
VX-970 (VE-822), an orally bioavailable derivative of VE-821.22
We first confirmed that VX-970 mirrored results with VE-821 and
demonstrated potentiation of hydroxyurea and gemcitabine in
MV4-11 and primary AML cells (supplemental Figure 5A-B).
MV4-11 cells engineered to express firefly luciferase were intra-
femorally transplanted into immunocompromised Rag22/2gc2/2
mice. Bioluminescent imaging demonstrated localized femoral
engraftment 7 days after injection, with signal developing in
other parts of the body (liver, cranium, noninjected femur)
between days 15 and 18 in untreated mice. Treatment was
initiated 7 days after injection when disease was localized to the
injected femur and before the emergence of luciferase signal
elsewhere. Mice were treated with 100 mg/kg gemcitabine on
days 1, 4, 8, and 11 and/or VX-970 on days 1-5 and 8-12.
Treatment with gemcitabine monotherapy led to significant early
disease control by the end of the 2-week treatment period
(Figure 5A-B) and significantly improved overall survival com-
pared with controls (P 5 .001; Figure 5C). Nevertheless, signal
returned in all mice, and relapsed AML required the humane
euthanasia of all animals randomly assigned to this arm. VX-970
monotherapy had no discernible effect on early disease control
but did have a very modest effect on overall survival (Figure
5A-C). Treatment with gemcitabine and VX-970 combined
conferred very significant early disease control, eliciting sub-
stantial reductions in signal by day 14 in all 6 mice randomly
assigned to this arm (Figure 5A-B) and also conferred a
significantly improved overall survival (P 5 .001; Figure 5C). Of
the 6 animals in this arm, 1 was censored because of an unrelated
condition on day 32 with no evidence of disease, 1 reached the
specified humane end point (as a result of AML symptoms) on day
102, and 4 animals remained disease free when the experiment was
terminated on day 165.
We next investigated the efficacy of gemcitabine plus VX-970
when treatment was delayed such that the luciferase signal was
no longer localized to the femur but was disseminated to other
parts of the body. As seen with localized disease, there was
significant treatment-induced control of disseminated disease
Figure 1. ATR inhibition using small molecule inhibitors or shRNA-mediated gene knockdown potentiates the inhibitory effects of hydroxyurea (HU) and
gemcitabine (Gem) in AML cell lines. (A) To confirm target engagement, AML cell lines were exposed to 100 mM HU (or vehicle control) for 1 hour in the presence of
1 mM VE-821 (or DMSO control), and western blotting was performed for ATR and pCHK1 (Ser345). Expression of pCHK1 is expressed relative to the HU-only lane for each
cell line. (B-C) AML cell lines were treated with (B) HU or (C) Gem either alone (purple circles), in combination with 10 mM NU6027 (red circles), or in combination with 1 mM
VE-821 (blue circles), and cell density (relative to respective vehicle controls) was determined after 96 hours. PFs were calculated for both ATR inhibitors (NU6027, red text;
VE-821, blue text) at the highest dose of HU or Gem. (D) U937 and MV4-11 AML cells were treated with escalating does of VE-821 and/or drug (Gem or HU). CI values ,1
indicate synergy between drug combinations. (E) Western blotting for ATR was performed at 24-hour intervals to confirm shRNA-mediated knockdown in HL-60 ATR (con)
cells with constitutive ATR knockdown (left blot) and HL-60 ATR (ind) cells with doxycycline-induced ATR knockdown (right blot). (F-G) HL-60 ATR (con) cells (green circles,
left chart) and HL-60 ATR (ind) cells (yellow circles, right chart) and their respective controls were treated with (F) HU or (G) Gem, and cell growth and PFs were determined
as above. For all western blots, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control, and for all potentiation assays, data represent the
mean 6 standard deviation (SD) of 3 independent experiments. See supplemental Figures 2, 3, and 5A. dox, doxycycline; NTC, non-target control.
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with complete eradication of luciferase signal in 4 of 6 mice 7 days
after the end of the second treatment cycle (supplemental
Figure 6). Of the 6 animals treated, 4 eventually reached specified
humane end points resulting from AML (days 64, 71, 88, and 143),
but 2 had no evidence of luciferase signal (or disease) when the
experiment was terminated on day 143. Histologic examination of
tissues from these mice confirmed the absence of human AML
markers at the termination of the experiment (Figure 6A). There
was no evidence of bone marrow dysmorpology in nonengrafted
animals treated with single-agent VX-970, which provides further
evidence supporting the safe use of ATR inhibitors as therapy in
AML (Figure 6B).
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of 1 mM VE-821 or DMSO control. Cell cycle profiles were determined by propidium iodide staining (in 2 3 105 cells) immediately pretreatment (0 hours) and at 8-hour
intervals posttreatment, as indicated. (B) MV4-11 cells were preincubated with 5 nM Gem, 15 mM HU, 50 nM Ara-C, or vehicle control for 1 hour, then pulse labeled with
25 mM 5-iodo-29-deoxyuridine (IdU) for 40 minutes, followed by 250 mM 5-chloro-29-deoxyuridine (CldU) for 40 minutes (with maintenance of exposure to drug throughout).
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See supplemental Figure 4.
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Discussion
Targeting components of the DDR is an attractive approach for
treating cancers that harbor high levels of endogenous replication
stress considering that many anticancer treatments function primarily in
S phase via inhibition of DNA replication. However, the identification of
efficacious drug combinations remains challenging given the extensive
genetic heterogeneity intrinsic to most cancers, including AML.
Evidence suggests that some cancers, such as those with
MYC activation or ARID1A mutation, have sufficiently high
endogenous levels of replication stress to justify use of ATRi
as monotherapy.23-26 Despite evidence of synthetic lethality with
activated oncoproteins in other cancer models, we observed only
very modest single-agent ATRi activity in AML. Our data and data
from the majority of published preclinical studies suggest a
strategy in which ATR inhibitors are likely to be most efficacious in
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combination with therapy that generates additional replication
stress.22,27,28 Specifically, we show here that ATR inhibition is
particularly effective in combination with hydroxyurea and gemcitabine,
agents that induce replication fork collapse, suggesting that
overreliance on the DDR machinery renders AML cells particularly
susceptible to ATR inhibition.
A
C D
B
0
-4 -3 -2
log [HU] mM
Ce
ll g
ro
wt
h 
(%
)
-1 0 1
20
40
60
80
100
de novo AML1
0
-4 -3 -2
Ce
ll g
ro
wt
h 
(%
)
-1 0
20
40
60
80
100
de novo AML 3
0
-4 -3 -2
Ce
ll g
ro
wt
h 
(%
)
-1 0 1
20
40
60
80
100
Healthy donor 1
0
-4 -3 -2
Ce
ll g
ro
wt
h 
(%
)
-1 0
20
40
60
80
100
relapsed AML
0
-5 -4 -3
log [gem] mM
Ce
ll g
ro
wt
h 
(%
)
-2 -1 0 -5 -4 -3 -2 -1 0
20
40
60
80
100
de novo AML1
0
log [gem] mM
Ce
ll g
ro
wt
h 
(%
)
20
40
60
80
100
de novo AML2
0
-4 -3 -2
log [HU] mM
log [HU] mM log [HU] mM
log [HU] mM
0
-4 -3 -2
Ce
ll g
ro
wt
h 
(%
)
-1 0 1
20
40
60
80
100
Healthy donor 2
log [HU] mM
0
-5 -4 -3
Ce
ll g
ro
wt
h 
(%
)
-2 -1 0
20
40
60
80
100
Healthy donor 1
log [gem] mM
0
-5 -4 -3
Ce
ll g
ro
wt
h 
(%
)
-2 -1 0
20
40
60
80
100
Healthy donor 2
log [gem] mM
Ce
ll g
ro
wt
h 
(%
)
-1 0 1
20
40
60
80
100
t-AML1
0
-4 -3 -2
log [HU] mM
Ce
ll g
ro
wt
h 
(%
)
-1 0
20
40
60
80
100
t-AML2
0
-5 -4 -3
log [gem] mM
Ce
ll g
ro
wt
h 
(%
)
-2 -1 0
20
40
60
80
100
t-AML1
0
-4 -3 -2
log [gem] mM
Ce
ll g
ro
wt
h 
(%
)
-1 0
20
40
60
80
100
t-AML2
0
-4 -3 -2
log [HU] mM
Ce
ll g
ro
wt
h 
(%
)
-1 0 1
20
40
60
80
100
de novo AML2
DMSO
5 µM VE-821
DMSO
5 µM VE-821
DMSO
5 µM VE-821
DMSO
5 µM VE-821
Figure 4. VE-821-mediated ATR inhibition potentiates the cytotoxic effects of HU and Gem in mononuclear cells isolated from AML patients. (A-B) Bone
marrow mononuclear cells from up to 6 AML patients (3 de novo AML, 1 relapsed AML, and 2 t-AML patients) were treated with (A) HU or (B) Gem in combination with 5 mM
VE-821 (blue circles) or DMSO control (red circles). Cell survival (relative to respective vehicle controls) was determined after 72 hours by addition of resazurin sodium salt.
(C-D) CD341 cells from 2 healthy donors were treated with (C) HU or (D) Gem, and cell survival was determined as above. See supplemental Figure 5C.
1164 FORDHAM et al 22 MAY 2018 x VOLUME 2, NUMBER 10
.For personal use onlyon June 11, 2019. by guest  www.bloodadvances.orgFrom 
We show that loss of RNR induces a pCHK1 response and
attenuates proliferation in AML cells that is potentiated by
inhibition of ATR. These data suggest that stalled replication
forks resulting from RNR inhibition are signaled via ATR and are
highly repairable via downstream pathways. In this scenario,
ATR functional status is a major determinant of AML cell fate,
suggesting a mechanism to explain why the antileukemic activity
of gemcitabine and hydroxyurea, both inhibitors of RNR, are
significantly potentiated by ATRi. Of potential importance,
inhibition of RNR by hydroxyurea is reversible, whereas inhibi-
tion by gemcitabine is irreversible.29 Consistent with this, we
observed a significantly longer induction of pCHK1 after single-
agent gemcitabine treatment compared with hydroxyurea (data
not shown).
The prevailing data suggest a mechanism whereby targeting ATR
is particularly effective at inducing cell death in the setting of high
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and sustained levels of replication stress resulting from stalled
replication. In support of this hypothesis, ATRi is effective when
delivered in combination with small molecular inhibitors of both de
novo (RNR) and salvage (deoxycytidine kinase) nucleotide bio-
synthesis pathways.30 Inhibition of either of these pathways results
in lower dNTP levels and induces stalled replication forks, but loss of
1 pathway can be partly compensated by upregulation of the other.31
However, simultaneous inhibition of both pathways is particularly
effective at inducing sustained replication stress, rendering cells
susceptible to ATRi.30 Our data demonstrate that this model can be
therapeutically exploited via the use of ATR inhibitors in combination
with hydroxyurea or gemcitabine, clinically approved agents that
directly abrogate RNR function that compromise dNTP pools and
induce replication stress.17,18 Furthermore, evidence suggests that
ATR signaling also plays a direct role in regulating dNTP metabolism.
Inhibition of ATR reduces dNTP levels in cancer cell lines,32 which
has been linked to inhibition of the RNR RRM2 subunit.6,33
Le and colleagues30 demonstrated downregulation of both RRM1
and RRM2 in lymphoblastic leukemia cells after ATR inhibition,
and targeted knockdown of RRM2 attenuates the deoxycytidine
monophosphate pool and reduces incorporation of deoxycytidine
triphosphate into replicating DNA.30 These data demonstrate that
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ATR inhibitors gemcitabine and hydroxyurea can have an effect on
dNTP pools via inhibition of RNR.
Analogs of fludarabine and cladribine also have some RNR inhibitory
activity, although it is reversible,34,35 which might explain potentiation
by ATRi in some AML cell lines. However, analogs of cytarabine do not
inhibit RNR,36 and although we observed cytarabine-induced pCHK1
in some AML cell lines that was attenuated by ATRi (data not shown),
there was no consistent evidence that ATR inhibition or knockdown
potentiated cytarabine-induced growth inhibition, cell cycle progres-
sion, or replication fork progression. However, ATRi inhibition did
potentiate the growth inhibitory effects of cytarabine in THP-1 AML
cells, consistent with data reported by others.37 It remains possible
that somatic genetic background could affect sensitivity to ATR
inhibitors in combination with cytarabine. It is also possible that higher
doses of ATR inhibitor might potentiate cytarabine-induced growth
inhibition. The prevailing evidence suggests that cytarabine-induced
stalled replication forks are repaired inefficiently via ATR-mediated
mechanisms compared with those arising as a result of RNR inhibition
and also that the contribution made by ATR to repair may be modified
by somatic genetic background.
Our data warrant clinical investigation of ATR inhibitors as AML therapy
in combination with agents that target RNR, including gemcitabine and
hydroxyurea. In addition to demonstrated efficacy and widespread
clinical use for solid malignancies, gemcitabine has clinical activity with
acceptable toxicity in refractory and relapsed AML.38-41 Data from a
phase 1 trial of gemcitabine in solid tumors provides evidence of its
activity in combination with VX-970.42 Hydroxyurea also has efficacy in
AML and is primarily used in a palliative setting for leukocytoreduction,
particularly in elderly patients with low tolerance for more aggres-
sive therapies.43 Gemcitabine inhibits the RRM1 subunit, whereas
hydroxyurea inhibits the catalytic RRM2 subunit.44 We show that
depletion of RRM1 or inhibition of RRM2 both synergize with ATR
inhibition, demonstrating that potentiation by ATRi is not RNR subunit
specific. We observed potentiation of 3-AP–induced growth inhibition
by VE-821, suggesting that direct targeting of RNR in combination with
ATRi could prove efficacious in the treatment of AML. Early phase
clinical trials of 3-AP demonstrate efficacy in aggressive myeloprolif-
erative neoplasms and refractory AML with an acceptable safety
profile,45-50 which paves the way toward proof-of-concept studies in
combination with ATR inhibitors.
In summary, our data demonstrate that administration of an ATR
inhibitor at biologically effective doses is well tolerated in a murine
model, with no apparent effects on normal marrow morphology.
Furthermore, we show that ATRi significantly potentiates the activity
of hydroxyurea and gemcitabine in AML cells. ATR loss is synergistic
with inhibition of RNR, which identifies this as a mechanism that
potentially explains the potency of combinations incorporating ATRi
and agents that target RNR. The generation of a therapeutic window
via administration of an intrinsically nontoxic ATR inhibitor could be
particularly important for elderly AML patients who often have low
tolerance for standard remission induction regimens. Our findings will
also inform the deployment of ATR inhibitors for the treatment of AML
and other hematologic malignancies.
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